• Users Online: 538
  • Print this page
  • Email this page
  • Email this page
  • Email this page
  • Email this page

    Article Cited by others

ORIGINAL ARTICLE

Treatment response in patients with moderate-to-severe psoriasis who had inadequate response to prior secukinumab

Chiu Tai-Siang, Tsai Tsen-Fang

Year : 2019| Volume: 37| Issue : 3 | Page no: 129-133

   This article has been cited by
 
1 Associations between HLA-Cw1 and Systemic Treatment Response of Asian Psoriasis Patients
Shin-Shin Ho, Tsen-Fang Tsai
Molecular Diagnosis & Therapy. 2022;
[Pubmed]  [Google Scholar] [DOI]
2 Therapeutic drug monitoring in dermatology: the way towards dose optimization of secukinumab in chronic plaque psoriasis
Rani Soenen, Zhigang Wang, Lynda Grine, Erwin Dreesen, Lisa Schots, Els Brouwers, Paul Declerck, Debby Thomas, Jo Lambert
Clinical and Experimental Dermatology. 2022;
[Pubmed]  [Google Scholar] [DOI]
3 The Inflammatory Factor SNP May Serve as a Promising Biomarker for Acitretin to Alleviate Secondary Failure of Response to TNF-a Monoclonal Antibodies in Psoriasis
Lanmei Lin, Yilun Wang, Xiaonian Lu, Tianxiao Wang, Qunyi Li, Runnan Wang, Jinfeng Wu, Jinhua Xu, Juan Du
Frontiers in Pharmacology. 2022; 13
[Pubmed]  [Google Scholar] [DOI]
4 Treatment Response of Patients with Erythrodermic Psoriasis after Switching to Guselkumab
Cheng-Ying Chiang,Tsen-Fang Tsai
Dermatology and Therapy. 2021;
[Pubmed]  [Google Scholar] [DOI]
5 Secukinumab 2-weekly vs. 4-weekly dosing in plaque-type psoriasis
T.-F. Tsai
British Journal of Dermatology. 2021;
[Pubmed]  [Google Scholar] [DOI]
6 Secukinumab in patients with psoriasis who have responded inadequately to tumour necrosis factor inhibitor treatment
T.-F. Tsai
British Journal of Dermatology. 2020;
[Pubmed]  [Google Scholar] [DOI]
7 Secukinumab 2-weekly vs. 4-weekly dosing in patients with plaque-type psoriasis: results from the randomized GAIN study
K. Reich,A. Körber,U. Mrowietz,M. Sticherling,C. Sieder,J. Früh,T. Bachhuber
British Journal of Dermatology. 2020;
[Pubmed]  [Google Scholar] [DOI]
8 Effectiveness and safety of secukinumab for psoriasis in real-world practice: analysis of subgroups stratified by prior biologic failure or reimbursement
Tzong-Yun Ger, Yu-Huei Huang, Rosaline Chung-yee Hui, Tsen-Fang Tsai, Hsien-Yi Chiu
Therapeutic Advances in Chronic Disease. 2019; 10: 2040622319
[Pubmed]  [Google Scholar] [DOI]

 

Read this article